Teva Pharmaceuticals, Ltd. announced its US launch of the first generic version of twice daily PERFOROMIST®,formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
[Teva Pharmaceuticals, Ltd.]
7753456
{7753456:nan}
apa
50
1
163829
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
